Arestat™ is based on a number of fundamentally novel insights into interactions between formulation excipients and proteins, allowing control of protein behaviour under various stress conditions.

The application of this technology can deliver differentiation in the form of products with superior kinetics, stable ready-to-administer products for IV delivery, concentrated liquid doses for self-administration, and desirable pharmacokinetic and pharmacodynamic profiles.

The various aspects of our Arestat™ technology platform are protected by over 50 granted patents, and 20 pending patent applications.

  • Differentiated biosimilars with IP Protection

  • Intravenous to subcutaneous switch

  • Lyophilised powder to liquid switch

  • High concentration antibodies

  • Superior peptides

  • Thermostable vaccines and therapeutics